Abridged Unaudited Consolidated Financial Statements For The Three Months Ended 31 August 2017 GO LIFE INTERNATIONAL LIMITED (Incorporated in the Republic of Mauritius) (Registration number: 098177 C1/GBL) Primary Listing SEM share code: GOLI.N0000 Secondary Listing JSE share code: GLI ISIN: MU0330N00004 (“the Company” or “Go Life International”) Abridged Unaudited Consolidated Financial Statements For The Three Months Ended 31 August 2017 DIRECTORS’ COMMENTARY The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Category 1 Global Business License (License No - C110009034) issued by the Mauritius Financial Services Commission. Go Life International is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius(SEM) on 07 July 2011. The Company was previously structured as a PCC under the PCC Act and was converted into a limited company and changed its name to Go Life International Limited by way of a shareholder resolution on 31 March 2015. The name change was approved on 16 June 2015 in anticipation of the inward listing on the Alternative Exchange (“AltX”) of the Johannesburg Stock Exchange (“JSE”) and the conversion to a limited company became effective on 03 June 2016. PRIMARY OBJECTIVE Go Life International was established to leverage the strength of existing South African nutraceutical companies, Go Life Health Products and Gotha Health Products (collectively Go Life SA), and to drive the presence of the South African products and brands across the global nutraceutical market. Go Life product range prides itself on its natural products and supplements originated in the womb of Africa which are scientifically developed for the world and enhanced through unique technology. After the secondary listing on the AltX, new opportunities and strategic partners have come into being which have now positioned Go Life International to be a full-fledged medical and healthcare services company. COMPANY OUTLOOK Go Life Health Products holds 100% of Gotha Health Products, Bon Health Properties (100%) and 49% of Bon Health Operations. Go Life Health Products focuses on nutraceuticals which aims to promote good health, aid in the prevention of certain diseases or helps with recovery from illness. The product is still primarily sold in the Eastern Cape but initiatives are being pursued to expand distribution channels and areas. This will include appointing channel and other strategic partners. Bon Health has a frail care and retirement village focus which also includes Alzheimer’s and dementia centres. There is an international need for such facilities and Bon Health has a highly effective and successful reputation and knowledge in managing such facilities. On the 22nd of February 2017 the Company signed an agreement with Elysium Healthcare Africa, giving the Company exclusive access to a full range of health products, generic medicines, services and equipment; and also to 25 countries in which Elysium Healthcare Africa has access. This relationship has attracted significant interest and a number of activities have commenced to progress various opportunities. DIVIDENDS No dividends were authorized or paid during the period under review. STATEMENT OF FINANCIAL POSITION THE GROUP THE GROUP THE COMPANY THE COMPANY 31 Aug 2017 31 May 2017 31 Aug 2017 31 May 2017 USD USD USD USD ASSETS Non - Current Assets 36 658 985 36 621 374 34 921 774 34 817 190 Investments in Associates/Subsidiary 998 538 957 205 34 921 774 34 817 190 Intangible Assets 28 857 769 28 857 769 - - Property Plant and Machinery 6 802 678 6 806 400 - - Current Assets 717 440 640 154 1831 7 372 Trade and other Receivables 334 642 278 450 451 - Cash and Cash Equivalents 382 798 361 704 1 380 7 372 TOTAL ASSETS 37 376 425 37 261 528 34 923 605 34 824 562 EQUITY Capital and Reserves 34 176 400 34 043 539 34 874 149 34 757 550 Share Capital 34 965 300 34 965 300 34 965 300 34 965 300 Revenue Deficit (795 900) (921 761) (91 151) (207 750) LIABILITIES Non - Current Liabilities 2 988 122 2 988 122 - - Loan - Shareholders 2 988 122 2 988 122 - - Current Liabilities 218 903 229 867 49 456 67 012 Trade and other Payables 218 903 229 867 49 456 67 012 TOTAL EQUITY AND LIABILITIES 37 376 425 37 261 528 34 923 605 34 824 562 STATEMENT OF CASH FLOWS THE GROUP THE GROUP THE COMPANY THE COMPANY 31 Aug 2017 31 May 2017 31 Aug 2017 31 May 2017 USD USD USD USD Profit/ Loss for the Period 119 304 109 944 117 998 109 188 Share of profit of associate (32 393) (28 535) (32 393) (28 535) Net Cash from Operating activities 86 911 81 409 85 605 80 653 Trade and other receivables (334 642) (278 450) - - Trade and other payables 218 903 229 867 49 456 67 012 Cash movement for the period (28 828) 32 826 36 149 13 641 Cash and cash equivalents - Start of period 415 624 382 798 13 732 91 Cash and cash equivalents – End of period 386 796 415 624 49 881 13 732 STATEMENT OF PROFIT / LOSS AND OTHER COMPREHENSIVE INCOME THE GROUP THE GROUP THE COMPANY THE COMPANY 31 Aug 2017 31 May 2017 31 Aug 2017 31 May 2015 USD USD USD USD Revenue 438 169 343 723 - - Expenses (280 194) (193 523) (1 306) (756) PROFIT/ (LOSS) FROM OPERATIONS 157 975 150 200 (1 306) (756) Share of profits - Associates 32 393 28 408 - - Finance Income - 2 565 - - 190 368 181 173 (1 306) (756) Finance costs (71 064) (71 064) - - PROFIT / (LOSS) BEFORE TAXATION 119 304 110 109 119 304 109 944 Taxation - - - - TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 119 304 110 109 117 998 109 188 SEGMENTAL REPORTING – 3 MONTHS ENDED 31 AUG 2017 Nutraceutical Property Frail care Total Associate USD USD USD USD Statement of net profit/loss Revenue 216 938 188 838 32 393 438 169 Interest expenses - (71 064) - (71 064) Income Tax - - - - Adjusted Headline earnings (20 049) 105 654 32 393 117 998 Net profit/(loss) for the period Statement of financial position Total Assets 29 582 209 6 802 678 998 538 37 383 425 Total Borrowings - (2 988 122) - (2 988 122) SEGMENTAL REPORTING – 3 MONTHS ENDED 31 MAY 2017 Frail care Nutraceutical Property Associate Total USD USD USD USD Statement of net profit/loss Revenue 147 037 168 458 28 235 343 730 Interest expenses - (71 064) - (71 064) Income Tax - - - - Adjusted Headline earnings (16 441) 97 394 28 235 109 188 Net profit/(loss) for the period Statement of financial position Total Assets 29 497 923 6 806 400 957 205 37 261 528 Total Borrowings - (2 988 122) - (2 988 122) RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS THE GROUP THE GROUP 31 Aug 2017 31 May 2017 USD USD Basic earnings 117 998 109 188 Headline earnings 117 998 109 188 Adjusted headline earnings / Distributable earnings 117 998 109 188 Weighted average number of shares 900 000 000 900 000 000 Basic and diluted earnings per share (USD cents) 0.0131 0.0121 Basic and diluted headline earnings per share (USD cents) 0.0131 0.0121 Adjusted headline earnings per share (USD cents) 0.0131 0.0121 STATEMENT OF CHANGES IN EQUITY Stated Revenue Total THE GROUP Capital Deficit Equity USD USD USD Consolidation adjustment on acquisition of investment 34 965 300 - 34 965 300 Total Comprehensive Income for the period - 117 998 117 998 Consolidation adjustments (918 591) (918 591) Balance as at 31 August 2017 34 965 300 (800 593) 34 164 707 Stated Translation Revenue Total THE COMPANY capital Reserve Deficit Equity USD USD USD USD Balance as at 01 March 2017 34 956 300 - (176 250) 9 488 850 Total Comprehensive Income for the period - - 109 188 109 188 Share Capital Issued - - - - Reclassification adjustment - - - - Balance as at 31 May 2017 34 956 300 - (67 062) 9 598 038 Balance as at 01 June 2017 34 965 300 - (67 062) 9 598 038 Total Comprehensive Income for the period - - 117 998 117 998 Balance as at 28 February 2017 34 965 300 - 50 936 9 716 036 Notes The Company is required to publish financial results for the 3 months ended 31 August 2017 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited consolidated financial statements for the 3 months ended 31 August 2017 (“financial statements”) have been prepared in accordance with the measurement and recognition requirements of IFRS, the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listing requirements. The accounting policies adopted in the preparation of the financial statements are consistent with those applied in the preparation of the audited financial statements of the year ended 28 February 2017. Copies of the Abridged Unaudited Consolidated Financial Statements for The 3 Months Ended 31 August 2017 and the Statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the Company Secretary at the Registered Office of the Company at Beau Plan business Park, Pamplemousses 21001 , Mauritius. This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.20 and section 88 of the Securities Act of Mauritius 2005. The Board accepts full responsibility for the accuracy of the information contained in these financial statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 31 August 2017 that require any additional disclosure or adjustment to the financial statement. By order of the Board AceTer Global Limited Company Secretary 13 October 2017 For further information please contact: AceTer Global Limited Arbor Capital Sponsors (230) 204 080 +27 (0) 11 480 8500 SPONSOR Arbor Capital Sponsors Proprietary Limited Date: 13/10/2017 02:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.